A retrospective analysis of post transplant lymphoproliferative disorder following liver transplantation

ConclusionOutcomes reported in this study are favourable and comparable to those reported previously. The addition of rituximab did not appear to have improved outcomes in this series, although a significant proportion of patients were able to avoid chemotherapy.This article is protected by copyright. All rights reserved.

http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fejh.12988

Source: European Journal of Haematology - November 1, 2017 Category: Hematology Authors: Feras Al Fararjeh, Shameem Mahmood, Phaedra Tachtatzis, Deborah Yallop, Stephen Devereux, Piers Patten, Kosh Agrawal, Abid Suddle, John O'Grady, Nigel Heaton, Robert Marcus, Shireen Kassam Tags: Original Article Source Type: research